Form 10-Q Cara Therapeutics, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
Cara Therapeutics (CARA) Tops Q3 EPS by 8c
November 10, 2015 7:21 AM ESTCara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.19), $0.08 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.77 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More